These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 30777929

  • 21. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
    Yao J, Li Z, Wang X, Xu P, Zhao L, Qian J.
    Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
    [Abstract] [Full Text] [Related]

  • 22. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
    Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, Zhang X, Huang Y, Zhang R, Wei J, Ali DW, Michalak M, Chen XZ, Tang J.
    Mol Cancer; 2020 Jul 29; 19(1):118. PubMed ID: 32727463
    [Abstract] [Full Text] [Related]

  • 23. LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition.
    Song S, Yu W, Lin S, Zhang M, Wang T, Guo S, Wang H.
    Cancer Biol Ther; 2018 Jul 03; 19(7):573-583. PubMed ID: 29667486
    [Abstract] [Full Text] [Related]

  • 24. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G, Ji L, Ke M, Ou Z, Tang N, Li Y.
    Biomed Pharmacother; 2018 Oct 03; 106():523-531. PubMed ID: 29990840
    [Abstract] [Full Text] [Related]

  • 25. MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.
    Hu W, Liu Q, Pan J, Sui Z.
    Biomed Pharmacother; 2018 Sep 03; 105():887-898. PubMed ID: 30021382
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.
    Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z.
    Mol Oncol; 2013 Jun 03; 7(3):334-45. PubMed ID: 23177026
    [Abstract] [Full Text] [Related]

  • 28. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
    Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu P, Wei J, Jiang K, Miao Y.
    Oncol Rep; 2013 May 03; 29(5):1769-76. PubMed ID: 23440261
    [Abstract] [Full Text] [Related]

  • 29. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
    Gu J, Huang W, Wang X, Zhang J, Tao T, Zheng Y, Liu S, Yang J, Chen ZS, Cai CY, Li J, Wang H, Fan Y.
    Mol Cancer; 2022 May 10; 21(1):112. PubMed ID: 35538494
    [Abstract] [Full Text] [Related]

  • 30. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
    Shen Y, Pan Y, Xu L, Chen L, Liu L, Chen H, Chen Z, Meng Z.
    Tumour Biol; 2015 Jun 10; 36(6):4525-34. PubMed ID: 25722110
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.
    Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y, Mori M, Doki Y.
    Br J Cancer; 2013 Jul 23; 109(2):502-11. PubMed ID: 23799850
    [Abstract] [Full Text] [Related]

  • 33. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
    Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J.
    PLoS One; 2008 Jul 23; 3(11):e3695. PubMed ID: 19002265
    [Abstract] [Full Text] [Related]

  • 34. MiR-760 enhances sensitivity of pancreatic cancer cells to gemcitabine through modulating Integrin β1.
    Yang D, Hu Z, Xu J, Tang Y, Wang Y, Cai Q, Zhu Z.
    Biosci Rep; 2019 Nov 29; 39(11):. PubMed ID: 31693728
    [Abstract] [Full Text] [Related]

  • 35. miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.
    Cao J, Wang Q, Wu G, Li S, Wang Q.
    Int Urol Nephrol; 2018 Oct 29; 50(10):1811-1819. PubMed ID: 30117016
    [Abstract] [Full Text] [Related]

  • 36. Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
    Rüstem DG, Atay S, Aydin HH, Ak H.
    Anticancer Agents Med Chem; 2021 Oct 28; 21(16):2204-2215. PubMed ID: 33397269
    [Abstract] [Full Text] [Related]

  • 37. Impact of Oncogenic Targets Controlled by Tumor-Suppressive miR-30a-5p in Pancreatic Ductal Adenocarcinoma.
    Nepal P, Hozaka Y, Tanaka T, Wada M, Asai S, Minemura C, Idichi T, Arigami T, Kurahara H, Seki N, Ohtsuka T.
    Anticancer Res; 2021 Oct 28; 41(10):4821-4836. PubMed ID: 34593431
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.
    Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, Aboukameel A, Padhye S, Philip PA, Sarkar FH.
    PLoS One; 2011 Mar 09; 6(3):e17850. PubMed ID: 21408027
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.